Welcome To Website IAS

Hot news
Achievement

Independence Award

- First Rank - Second Rank - Third Rank

Labour Award

- First Rank - Second Rank -Third Rank

National Award

 - Study on food stuff for animal(2005)

 - Study on rice breeding for export and domestic consumption(2005)

VIFOTEC Award

- Hybrid Maize by Single Cross V2002 (2003)

- Tomato Grafting to Manage Ralstonia Disease(2005)

- Cassava variety KM140(2010)

Centres
Website links
Vietnamese calendar
Library
Visitors summary
 Curently online :  6
 Total visitors :  8508312

US FDA Releases Guidance for Heritable Intentional Genomic Alterations in Animals
Monday, 2024/06/03 | 08:22:07

ISAAA May 29, 2024

 

In May 2024, the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) released Guidance for Industry (GFI) #187A “Heritable Intentional Genomic Alterations in Animals: Risk Based Approach” and draft GFI #187B “Heritable Intentional Genomic Alterations in Animals: The Approval Process” to clarify requirements and recommendations for developers of intentional genomic alterations (IGAs) in animals.

 

FDA defined IGAs in animals as “changes to an animal's genomic DNA produced using modern molecular technologies, which may include random or targeted DNA sequence changes including nucleotide insertions, substitutions, or deletions.” IGAs in animals have been used in various applications for improving human and animal health.

 

GFI #187A describes a risk-based regulatory approach to oversee IGAs in animals. The approach categorizes products into three levels: Category 1 products, which do not require consultation before marketing; Category 2 products, which may not need an approval application if risks are understood and mitigated; and Category 3 products, which require FDA review and approval based on data requirements proportionate to the associated risk.

 

The draft of GFI #187B provides technical guidance for obtaining FDA approval for IGAs in animals. It applies to IGAs categorized as Category 2 or 3 in GFI #187A. The FDA CVM intends to finalize GFI #187B in the future after consultations with stakeholders.

 

For more information, read the final guidance document of GFI #187A and the draft guidance document of GFI #187B on the FDA website.

 

Back      Print      View: 163

[ Other News ]___________________________________________________
  • Australia`s Gene Regulator OGTR Invites Comments on Field Trial of GM Perennial Ryegrass
  • Long Lost Chromosome Increases Nitrogen Efficiency of Modern Maize
  • Modified Agrobacterium Strain Useful for Switchgrass Transformation
  • Study Reveals Role of Soybean 14-3-3 Gene on White Mold Resistance
  • CIMMYT Study Says Breeding New Crops Must Adapt to Climate Change
  • Researchers Identify Genes to Help Fruit Adapt to Droughts
  • Kenyans Need to Turn to GM Crops to Combat Drought
  • 28-Million-Year-Old Gene Protects Plants Against Caterpillars
  • Agronomists Find Wheat Varieties Resistant to Enzyme Depletion
  • Root Structure Mapped Out to Identify Components of Drought Stress Tolerance in Rice
  • Scientists Report First use of CRISPR to Substitute Genes to Treat Patients with Cancer
  • Large Chinese Seed Companies Likely to Produce Gene-Edited Crops for Farmers – Study
  • Study Finds CRISPR-Cas9 Leads to Unexpected Genomic Changes
  • Plants Yield Better When Grown Among Genetically Similar Plants
  • Codex Alimentarius: FAO Director-General stresses key role of science and data in the Commission`s work
  • World Food Programme and ICRISAT: working to improve nutrition and build resilience in vulnerable communities
  • From Lab to Farm: Scientific research and its contribution to family farming and rural entrepreneurship
  • Chemists Create Artificial Photosynthesis 10 Times More Efficient than Existing Systems
  • Micro/Nanofluidics and Lab-on-Chip Based Emerging Technologies for Biomedical and Translational Research Applications - Part B
  • Scientists Identify Wheat Genetically Resistant to Fungus Causing Snow Mold

 

Designed & Powered by WEBSO CO.,LTD